Lantheus Holdings CAO Kimberly Brown Sells 463 Shares for Tax Withholding Purposes
Kimberly Brown, Chief Accounting Officer of Lantheus Holdings (NASDAQ:LNTH), sold 463 shares of common stock on August 17, 2026. This transaction, conducted at $100.91 per share, was for tax withholding purposes related to equity awards. Following the sale, Brown's direct ownership in the company stands at 13,263 common stock shares.
Lantheus Holdings, Inc. Stock 12‑Month Price Target Cut to $106.3, Implies 6% Upside
Lantheus Holdings, Inc.'s average 12-month price target has been adjusted to $106.3 by 8 analysts, a slight decrease from $107.16. This new target suggests a potential upside of approximately 6% from its August 18 closing price. The consensus rating for LNTH remains "Hold" among 11 analysts.
B.Riley downgrades Lantheus stock rating on Curium acquisition
B.Riley downgraded Lantheus Holdings (NASDAQ:LNTH) to Neutral from Buy and reduced its price target following Curium's agreement to acquire Lantheus. The acquisition is set at $102.50 per share plus potential contingent value rights, with the transaction expected to close in the first half of 2027. Despite the downgrade, InvestingPro data indicates Lantheus stock may still be undervalued.
Lantheus Holdings’ Alzheimer’s radiodiagnostic secures FDA approval
Lantheus Holdings has received FDA approval for its radiodiagnostic agent, Tauklarify, for identifying tau pathology in adults being evaluated for Alzheimer's disease. Tauklarify is used for PET imaging of the brain to identify tau neurofibrillary tangle (NFT) pathology, a key biomarker for Alzheimer's. The approval was based on two blinded read studies demonstrating high accuracy and inter-reader agreement.
Lantheus Wins FDA Approval for Alzheimer's Tau PET Imaging Agent
Lantheus Holdings has received FDA approval for Tauklarify, a PET imaging agent designed to detect tau neurofibrillary tangle pathology in adults being evaluated for Alzheimer's disease. This approval comes as Lantheus prepares for an $8 billion acquisition by Curium and positions Tauklarify in a diagnostic market that has recently seen a rise in blood-based tests and disease-modifying therapies for Alzheimer's. The company plans to support therapeutic programs while determining the path for broader commercial availability.
FDA approves Lantheus tau PET imaging agent for Alzheimer’s disease
The FDA has approved Lantheus Holdings’ TauKlarify (florquinitau F 18 injection), a PET imaging agent for identifying tau neurofibrillary tangle pathology in adults with cognitive impairment being evaluated for Alzheimer’s disease. While effective for Alzheimer's, its safety and effectiveness for other tauopathies have not been established. Lantheus plans to use TauKlarify for therapeutic development programs and is working towards broader commercial availability.
Lantheus Holdings’ Alzheimer’s radiodiagnostic secures FDA approval
Lantheus Holdings has received FDA approval for Tauklarify, a radiodiagnostic agent designed to identify tau pathology in adults being evaluated for Alzheimer's disease. Tauklarify is used in PET imaging of the brain to detect tau neurofibrillary tangle (NFT) pathology, a key biomarker for Alzheimer's. This approval is based on two blinded read studies that demonstrated high accuracy and strong inter-reader agreement.
Tauklarify PET approval for Lantheus in AD NFT pathology
Lantheus Holdings announced FDA approval for Tauklarify (florquinitau F 18 injection), a radiodiagnostic agent for PET imaging of the brain to identify tau neurofibrillary tangle (NFT) pathology in adults with cognitive impairment being evaluated for Alzheimer's disease. This approval is supported by two blinded read studies involving over 500 subjects. The company plans to continue supporting Alzheimer's therapeutic programs and assess broader commercial availability, noting the importance of tau PET imaging in understanding Alzheimer's.
FDA Approves Lantheus Imaging Drug for Alzheimer's Diagnostics
The FDA has approved Lantheus Holdings Inc.'s Tauklarify (florquinitau F 18 injection), an imaging drug for PET scans to diagnose Alzheimer's disease in adults with cognitive impairment. This radiodiagnostic agent helps identify tau neurofibrillary tangle pathology, with its approval backed by two studies demonstrating high accuracy. Lantheus plans to integrate Tauklarify into its Pharma Solutions business and evaluate broader commercial availability.
What Does Lantheus Holdings (LNTH) FDA Approval Mean For Its Alzheimer’s Push?
Lantheus Holdings received FDA approval for TAUKLARIFY, a tau PET imaging agent for Alzheimer's disease diagnostics, expanding its molecular imaging portfolio beyond prostate cancer. This approval strengthens Lantheus's position in the Alzheimer's imaging market and supports its strategy of diversifying revenue and meeting the growing demand for early diagnosis of the disease. However, the company still faces execution risks and competition from other players in the PET imaging space.
Weekly Buzz: LNTH, CBLL Win FDA Nod; AURA Cuts Jobs; TDY Buys VREX; CGEM, DFTX Meet Trial Goals
This weekly roundup of the global biopharma sector highlights significant events including regulatory approvals, corporate restructuring, and clinical trial successes. Key approvals were granted to Lantheus, Akeso, Galderma, Rhythm Pharmaceuticals, Acarix, Ceribell, Labcorp, and Bavarian Nordic. Additionally, the article covers workforce reductions at Aura Biosciences, Schrödinger, and aTyr Pharma, major deals and acquisitions involving RTW Bio, Mereo BioPharma, Teledyne, Jazz Pharmaceuticals, and Oculis, and positive clinical trial readouts for Cullinan, NeOnc Technologies, Definium Therapeutics, and Silence Therapeutics.
FDA Approves Lantheus Imaging Drug for Alzheimer's Diagnostics
The FDA has approved Lantheus Holdings Inc.'s Tauklarify (florquinitau F 18 injection) for PET scans to diagnose Alzheimer's disease in adults with cognitive impairment. This radiodiagnostic agent helps identify tau neurofibrillary tangle pathology. Lantheus plans to support Alzheimer's therapeutic programs and is evaluating commercial availability, with the approval backed by two studies showing high agreement in tau-PET image analysis.
FDA approves Lantheus’ tau imaging agent for Alzheimer’s disease
The FDA has approved Lantheus Holdings Inc.'s TAUKLARIFY (florquinitau F 18 injection), a tau imaging agent for Alzheimer's disease. This radiodiagnostic agent is intended for brain PET scans in adults with cognitive impairment to identify tau neurofibrillary tangle pathology. The approval is based on two blinded read studies involving over 500 subjects, demonstrating high positive and negative percent agreement and inter-reader agreement.
US FDA approves Lantheus' brain-imaging agent for Alzheimer's assessment
Lantheus Holdings Inc. has received FDA approval for its brain-imaging agent, Tauklarify (Florquinitau F 18 Injection), for assessing Alzheimer's disease through PET imaging. This approval allows for the detection of tau pathology in the brain, which is a key indicator of Alzheimer's. The company, focused on radiopharmaceuticals, aims to assist clinicians in diagnosing and monitoring diseases more effectively.
US FDA approves Lantheus' brain-imaging agent for Alzheimer's assessment
The U.S. FDA has approved Lantheus Holdings' radioactive agent, Tauklarify, for use in brain scans to assess Alzheimer's disease by making abnormal tau protein deposits visible. This approval was based on two studies involving over 500 participants. While the tau-imaging market is currently dominated by Eli Lilly's Tauvid, analysts project Tauklarify sales to reach less than $50 million by 2030, noting that the clinical use of tau imaging is still limited as there is no approved Alzheimer's treatment specifically targeting tau.
FDA approves Lantheus brain scan to identify tau in Alzheimer’s
Lantheus has received FDA approval for TAUKLARIFY (florquinitau F 18 injection), a PET imaging agent used to detect tau neurofibrillary tangle pathology in adults with cognitive impairment being evaluated for Alzheimer's disease. The approval is based on two blinded read studies demonstrating high diagnostic performance. While it is not for non-Alzheimer’s tauopathies and has warnings about potential misdiagnosis and radiation risk, Lantheus plans to integrate it into its Pharma Solutions business for Alzheimer’s therapeutic programs.
Farallon group (LNTH) discloses 5.58M-share, 8.6% position in Lantheus
Farallon Capital Management, L.L.C. and its related funds have reported a beneficial ownership of 5,583,479 shares of Lantheus Holdings, Inc. common stock, which represents 8.6% of the outstanding class as of June 30, 2026. This disclosure was made via an amended Schedule 13G filing. The shares are held through various investment partnerships managed by Farallon Capital Management, L.L.C., with managing and senior managing members exercising shared voting and dispositive power.
Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives Consensus Rating of "Hold" from Analysts
Lantheus Holdings, Inc. (NASDAQ:LNTH) has received a consensus "Hold" rating from analysts, with an average 12-month price target of $108.11. The company recently exceeded earnings and revenue expectations, reporting $1.55 EPS and $388.18 million in revenue. Institutional investors hold a significant 99.06% of the stock, with several firms increasing their positions.
Lantheus Holdings (LNTH) Agreed To Be Acquired, Is The Remaining Upside Already Priced In?
Lantheus Holdings (LNTH) is set to be acquired by Curium US LLC for up to US$8 billion, including US$102.50 cash per share and contingent value rights up to US$12.00 per share tied to product milestones. The stock currently trades at US$100.98, near the cash offer, and while analysts estimate a fair value of $104.08, the deal is expected to close in the first half of 2027, with the company remaining independent until then. This transaction introduces a blend of deal certainty and potential additional upside from the contingent value rights, but also carries risks related to deal completion and product performance.
Lantheus Holdings (LNTH) Agreed To Be Acquired, Is The Remaining Upside Already Priced In?
Curium US LLC has agreed to acquire Lantheus Holdings (LNTH) for US$102.50 in cash per share plus contingent value rights up to US$12.00 per share, with the deal expected to close in the first half of 2027. The article discusses whether the remaining upside is already priced in, noting that the stock currently trades close to the cash offer. It also highlights that analysts see the stock as modestly undervalued with a fair value of $104.08, but with potential risks if product performance doesn't meet expectations.
Pacer Advisors Inc. Reduces Stock Holdings in Lantheus Holdings, Inc. $LNTH
Pacer Advisors Inc. significantly reduced its stake in Lantheus Holdings, Inc. by 97.0% in the first quarter, selling 247,589 shares and retaining 7,704 shares valued at $584,000. Despite this, other institutional investors have recently modified their holdings, and 99.06% of the stock is still owned by hedge funds and institutional investors. Lantheus reported strong quarterly earnings, beating analyst estimates, but analyst sentiment is mixed with several downgrades to "hold" ratings.
Empowered Funds LLC Takes Position in Lantheus Holdings, Inc. $LNTH
Empowered Funds LLC initiated a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by purchasing 11,979 shares valued at approximately $909,000. This comes as Lantheus exceeded quarterly earnings expectations, reporting $1.55 EPS against a $1.30 consensus, though analyst sentiment has softened with several downgrades to "Hold." Institutional investors collectively own 99.06% of the company's stock.
Lantheus Holdings, Inc. $LNTH is Reinhart Partners LLC.'s 2nd Largest Position
Reinhart Partners LLC. has increased its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 2.2%, making it their second-largest holding and comprising 4.1% of their portfolio. Despite this, analyst sentiment has softened, leading to several downgrades to "Hold" and a consensus price target of $108.11. Lantheus recently reported strong quarterly earnings, beating analyst estimates for both EPS and revenue.
Lantheus (LNTH) Stock Shrugs Off Solid Profit As Margin Questions Linger
Lantheus Holdings (LNTH) stock saw a minimal price change despite solid Q2 earnings, with revenue meeting expectations and EPS remaining flat year-over-year. Investors are weighing the company's strong trailing P/E against questions about future growth pillars like Alzheimer’s diagnostics and operating leverage, especially after a slight decline in quarterly net income. The recent agreement for Curium to acquire Lantheus for up to US$8 billion further complicates the market's interpretation of its current performance and future prospects.
Lantheus Holdings Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lantheus Holdings, Inc. - LNTH
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Lantheus Holdings, Inc. (NasdaqGM: LNTH) to Curium US Holdings LLC. Shareholders are set to receive $102.50 per share in cash, plus potential additional payments of up to $12.00 per share via Contingent Value Rights. KSF is assessing whether this offer and the process leading to it adequately value the company.
Lantheus Holdings Inc earnings beat by $0.26, revenue topped estimates
Lantheus Holdings Inc (LNTH) reported strong second-quarter results, beating analyst expectations for both EPS and revenue. The company announced an EPS of $1.55 against an estimate of $1.29, and revenue of $388.2 million, surpassing the consensus of $362.32 million. LNTH's stock has shown significant growth, increasing by 9.07% in the last three months and 85.02% over the last year.
Lantheus (NASDAQ:LNTH) Reports Upbeat Q2 CY2026
Lantheus Holdings (NASDAQ:LNTH) reported strong Q2 CY2026 results, exceeding Wall Street expectations with revenue of $388.2 million and non-GAAP EPS of $1.55. Despite impressive five-year revenue and EPS growth, recent performance shows a slowdown, with analysts projecting a revenue decline for the next 12 months. The stock remained flat after the announcement, prompting further analysis on its investment potential.
Earnings Flash (LNTH) Lantheus Holdings, Inc. Posts Q2 Adjusted EPS $1.55 per Share, vs. FactSet Est of $1.30
Lantheus Holdings, Inc. (LNTH) reported Q2 adjusted EPS of $1.55 per share, surpassing the FactSet estimate of $1.30. The company also announced its Q2 revenue of $388.2 million, exceeding the FactSet estimate of $363.2 million. Additionally, Lantheus suspended its previously issued full-year 2026 financial guidance and is set to merge with Curium US LLC in an acquisition valued at up to $8 billion.
First Trust Advisors LP Purchases 44,713 Shares of Lantheus Holdings, Inc. $LNTH
First Trust Advisors LP significantly increased its stake in Lantheus Holdings, Inc. by 287.6% in Q1, acquiring 44,713 additional shares to hold a total of 60,258 shares valued at $4.57 million. This comes as Lantheus is set to be acquired by Curium for $102.50 per share in cash plus potential contingent value rights, with the transaction expected to close in the first half of 2027. Analyst sentiment for Lantheus is mixed, with a consensus "Hold" rating and an average price target of $108.11, while some shareholder law firms are investigating the fairness of the acquisition price.
Lantheus Holdings: Q2 Earnings Snapshot
Lantheus Holdings Inc. reported strong second-quarter earnings, surpassing Wall Street expectations. The diagnostic imaging company posted a profit of $1.11 per share and adjusted earnings of $1.55 per share, exceeding analyst estimates of $1.33. Revenue for the quarter also beat forecasts, coming in at $388.2 million compared to an expected $368.2 million.
Lantheus' Q2 Adjusted Earnings Fall, Revenue Rises
Lantheus (LNTH) reported a decrease in its Q2 adjusted earnings per diluted share to $1.55, although the company saw an increase in its revenue for the same quarter. The article notes that further details are available for premium subscribers.
Shareholder Alert: Ademi LLP investigates whether Lantheus Holdings, Inc. is obtaining a Fair Price for Public Shareholders
Ademi LLP is investigating Lantheus Holdings, Inc. (NASDAQ: LNTH) following its recently announced transaction with Curium, questioning if the deal provides a fair price for public shareholders. Lantheus shareholders are set to receive $102.50 per share in cash, plus Contingent Value Rights potentially worth up to an additional $12.00 per share. The investigation focuses on whether Lantheus' board fulfilled its fiduciary duties, especially considering the benefits insiders will receive and a significant penalty for competing bids.
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lantheus Holdings, Inc. (NASDAQ: LNTH)
Monteverde & Associates PC, a class action law firm, has announced an investigation into Lantheus Holdings, Inc. (NASDAQ: LNTH) following its proposed sale to Curium US Holdings LLC. Shareholders are set to receive $102.50 per share in cash, plus potential contingent value rights of up to $12.00 per share. The firm is inviting Lantheus shareholders to contact them to determine if the deal is fair.
Lantheus Stock Is Gaining Monday: What's Going On? - Lantheus Holdings (NASDAQ:LNTH)
Global investment firm CapVest Partners' portfolio company Curium is set to acquire Lantheus Holdings (NASDAQ:LNTH) in a deal valued at up to $8 billion. Lantheus shareholders will receive $102.50 per share in cash, plus contingent value rights potentially adding $12.00 per share, totaling up to $114.50 per share. William Blair analyst Andy Hsieh views this as an "excellent outcome" for Lantheus shareholders, citing the company's past operational challenges and the complementary nature of the combined entities.
Curium to buy Bedford-based Lantheus in deal worth up to $8B
Curium is set to acquire Lantheus, a 70-year-old radiopharmaceutical company based in Massachusetts, for up to $8 billion. The acquisition highlights a significant transaction in the radiopharmaceutical field, though the future of Lantheus' Massachusetts workforce remains uncertain. The deal was reported by the Boston Business Journal.
Curium Announces Definitive Agreement to Merge with Lantheus
Curium and Lantheus Holdings, Inc. have announced a definitive agreement for Curium to acquire Lantheus for up to $8.0 billion. The transaction involves a cash payment of $102.50 per share at closing, plus Contingent Value Rights of up to $12.00 per share tied to future commercial milestones of Lantheus' products. This merger aims to create a comprehensive radiopharmaceutical company with a global footprint, spanning diagnostics and therapeutics, to serve oncology, neurology, and cardiology patients in over 70 countries.
Lantheus Holdings to Be Acquired for Initial $6.7 Billion
Lantheus Holdings is set to be acquired by Curium, a radiopharmaceutical company backed by CapVest Partners, for an initial $6.7 billion. Curium will pay $102.50 per share in cash, representing a 2.9% premium over Friday's closing price. This acquisition follows Lantheus's comprehensive evaluation of strategic options.
LNTH Stock Alert: Halper Sadeh LLC is Investigating Whether Lantheus Holdings, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Lantheus Holdings, Inc. (NASDAQ: LNTH) to Curium US Holdings LLC for $102.50 per share in cash, plus potential additional contingent value rights. The firm is examining whether Lantheus and its board of directors failed to secure the best possible price for shareholders, conducted a fair sales process, or disclosed all material information. They encourage shareholders to contact them to discuss their rights and options.
Curium strikes up to $8 billion deal for radiopharma peer Lantheus
Curium has announced an agreement to acquire radiopharmaceutical company Lantheus Holdings for up to $8 billion. Lantheus shareholders will receive $102.50 per share in cash, with an additional $12 per share possible if certain sales targets are met by 2030. This represents a premium of approximately 14.9% over Lantheus's last closing price.
Lantheus Holdings to Merge With Curium US Holdings in Up to $8 Billion Transaction Closing in H1 2027
Lantheus Holdings is set to merge with Curium US Holdings in a transaction valued at up to $8 billion, which is expected to close in the first half of 2027. This acquisition will see Curium expanding its radiopharma capabilities by integrating Lantheus, a company focused on radiopharmaceuticals for diagnosing and monitoring various diseases. The deal highlights a significant consolidation in the medical equipment and supplies sector, specifically within the radiopharmaceutical market.
Curium Announces Definitive Agreement to Merge with Lantheus
Curium and Lantheus Holdings, Inc. have announced a definitive agreement for Lantheus to merge with a wholly-owned subsidiary of Curium US. The transaction, valued at up to $8.0 billion, will provide Lantheus shareholders with $102.50 per share in cash at closing, plus up to $12.00 per share in Contingent Value Rights tied to performance milestones. This merger aims to create a comprehensive radiopharmaceutical company with expertise in both diagnostics and therapeutics, serving over 70 countries.
Curium strikes up to $8 billion deal for radiopharma peer Lantheus
Curium has agreed to acquire radiopharmaceutical company Lantheus Holdings in a deal valued at up to $8 billion. Lantheus shareholders will receive $102.50 per share in cash, with potential additional payments of up to $12 per share based on sales targets, representing a 14.9% premium over Lantheus' last closing price. Lantheus CEO Mary Anne Heino stated that this transaction validates the company's innovation in radiopharmaceuticals.
Lantheus Holdings, Inc. Revenue Breakdown – NASDAQ:LNTH
Lantheus Holdings, Inc. (NASDAQ:LNTH) reported a total revenue of $1.54 billion USD last year. The PYLARIFY segment was the top performer, generating $989.12 million USD. The majority of the company's revenue, $1.46 billion USD, originated from the United States.
Lantheus Holdings Inc Revenue Breakdown – SWB:0L8
Lantheus Holdings Inc (SWB:0L8) generated €1.31 billion in revenue last year, with its PYLARIFY segment being the top performer, contributing €842.15 million. The United States was the largest geographical contributor, accounting for €1.24 billion of the total revenue. These figures show a slight increase in overall revenue compared to the previous year's €1.02 billion from the PYLARIFY segment and a decrease from the United States' €1.43 billion.
Lantheus Holdings (LNTH) Pipeline Narrative Holds Firm, Does The Stock Look Fully Valued?
Lantheus Holdings (LNTH) shares recently closed at US$101, showing a strong year-to-date return of 50.14% despite a recent 9% dip. The company is considered 3% undervalued with a fair value of $104 per share, driven by an expanding radiodiagnostic pipeline including multiple new product launches expected within the next 18 months. While optimistic about future growth, the narrative also acknowledges risks such as pricing pressure on PYLARIFY and uncertainties regarding how new launches will translate into earnings.
Lantheus Holdings (LNTH): Vanguard Portfolio Management reports 5.06% ownership stake
Vanguard Portfolio Management has reported a 5.06% ownership stake in Lantheus Holdings Inc. (LNTH) through a Schedule 13G SEC filing. This filing indicates beneficial ownership of 3,300,293 shares as of June 30, 2026, with Vanguard holding sole voting power over 61,822 shares and sole dispositive power over all reported shares. The ownership includes various Vanguard funds and managed accounts, and no single individual's interest exceeds 5%.
ETFs Investing in Lantheus Holdings Inc Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of Lantheus Holdings Inc. The ETFs are sorted by market value and provide details such as issuer, management style, focus, expense ratio, AUM, price, and 3-year total return. This information helps investors identify funds with Lantheus Holdings Inc. stock, offering diversified investment opportunities.
Lantheus Holdings (LNTH) Pipeline Narrative Holds Firm, Does The Stock Look Fully Valued?
Lantheus Holdings (LNTH) shares recently closed at US$101, showing positive momentum over the past year despite a recent monthly dip. The company's fair value is estimated at $104 per share, indicating it is slightly undervalued, a valuation supported by its radiodiagnostic pipeline with multiple new product launches expected within 18 months. However, the narrative also acknowledges risks such as pricing pressure and uncertainties with acquisitions and new launches.
Curium Reportedly Nears Acquisition Of Lantheus For Approximately $7 Billion
Curium Pharma is reportedly in advanced discussions to acquire radiopharmaceutical company Lantheus Holdings for approximately $7 billion, with potential for up to $8 billion through contingent value rights. This acquisition would merge two major nuclear medicine and diagnostic imaging companies, aiming to create a diversified radiopharmaceutical platform. The deal, if finalized, would involve a cash payment of $102 per share and additional payments tied to specific milestones, though no final agreement has been reached.
LNTH Maintained by Mizuho -- Price Target Lowered to $115
Mizuho maintained an "Outperform" rating for Lantheus Holdings (LNTH) but lowered its price target from $120 to $115. GuruFocus indicates that LNTH is currently 9.8% overvalued with a GF Value™ of $90.52 and a strong GF Score™ of 79/100, driven by high profitability and financial strength. Investors are advised to consider the mixed signals from guru activity and valuation before making investment decisions.
